NPL and Barrett esophagus: In our esophageal adenocarcinoma biomarker study, C9 glycoforms binding to each of the six short‐listed lectins (AAL, EPHA, JAC, NPL, PSA, WGA) was also significantly elevated in esophageal adenocarcinoma compared to the precursor benign condition, Barrett's esophagus but with some variability in healthy groups [18].